ABOUT US

Founded in 2001, Future Science Group is a progressive publisher focused on breakthrough medical, biotechnological and scientific research.

Future Science Group’s portfolio consists of two imprints, Future Science and Future Medicine. Both publish eBooks and peer-reviewed journals. In addition to this core publishing business, Future Science Group develops specialist eCommunities. Key titles and sites include the Journal of Comparative Effectiveness Research, Future Oncology, Bioanalysis Zone and the award-winning Regenerative Medicine.

The aim of Future Science Group is to serve the advancement of clinical practice and drug research by enhancing the efficiency of communication among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value for money, and uncompromisingly high standards.

Learn more about Future Science Group at www.future-science-group.com
Advancing clinical practice and drug research by enhancing communication

CONTENTS

About Us .................................. 2
Editorial Values ........................ 4
Readership ............................... 5
FAQs ...................................... 16
Contact Us ............................. 18

PUBLISHING SOLUTIONS

Realizing the Potential of your Research ......................... 7
Meeting Publication Deadlines ................................. 8
Illustrating your Findings ............ 9
Extending Reach ................. 10
Bespoke Solutions .................. 10

JOURNAL PORTFOLIO

Oncology ................................. 12
Cardiology ............................... 13
Neurology ................................. 13
Infectious Disease .................... 13
Immunology .............................. 14
Multi-disciplinary .................. 14
Bioscience & Biotechnology .......... 15
Future Science Group upholds the highest standards of editorial integrity, including disclosure and independent peer review. Future Science Group adheres to the guidelines set by COPE and ICMJE, endorses CONSORT, and follows the recommendations set by GPP2.

A unique feature of our editorial process is full in-house management; all Future Science Group managing editors are based in our London headquarters and hold a relevant bioscience degree, ensuring an informed evaluation of all of our content. All journals are also supported through guidance from their editorial boards.

Editorial board members represent the world’s most prestigious organizations, including:

- National Institutes of Health, USA
- Food and Drug Administration (FDA), USA
- Cedars–Sinai Medical Center, USA
- Harvard University, USA
- Cancer Research UK
- University College London, UK
- Cambridge University, UK
- Tel-Aviv University, Israel
- Karolinska Institute, Sweden
- Leiden University, The Netherlands
- National Cancer Center, Japan
- Seoul National University, Korea
- Peking University, China
- University of Melbourne, Australia
A global network of researchers, practitioners and policy-makers

READERSHIP

Our readership spans specialists in bioscience and medical practice across the globe.

Our key reader groups are:

- **Clinicians in primary and secondary care**, including: cardiologists, hematologists, immunologists, infectious disease specialists, neurologists, OB/GYN practitioners, oncologists and rheumatologists

- **Clinical, basic and translational researchers** in academia, industry, hospitals and government research organizations

- **Policy and decision-makers in government and industry**

- **Those with an interest in pharmaceutical patents/IP**

**FUTURE MEDICINE**
www.futuremedicine.com
28 journals; 137 eBooks

Last 12 months*:

- 4.3 million page views
- 1.2 million users
- 2.1 million abstract views
- 627,000 full-text downloads

**Top 5 countries**

- USA (28%)
- UK (9%)
- China (7%)
- India (6%)
- Canada (3%)

**FUTURE SCIENCE**
www.future-science.com
6 journals; 27 eBooks

Last 12 months*:

- 1.3 million page views
- 340,000 users
- 520,000 abstract views
- 230,000 full-text downloads

**Top 5 countries**

- USA (28%)
- UK (9%)
- India (9%)
- Germany (4%)
- China (7%)

*as of August 5, 2014
Launched in 2010, Publishing Solutions is the in-house publication planning support service for Future Science Group journals. With a flexible and collaborative approach, our aim is to help you meet your objectives before, during and after publication.

**REALIZING THE POTENTIAL OF YOUR RESEARCH**
Pre-submission advice from our in-house editorial team.

**MEETING PUBLICATION DEADLINES**
Publish in as little as 6 weeks from submission.

**ILLUSTRATING YOUR FINDINGS**
Rapid medical illustration and figure redrawing services.

**EXTENDING REACH**
Open and sponsored access, reprints and hosted content.

**BESPOKE SOLUTIONS**
Responsive and editorially led custom publishing solutions.
Time-sensitive publication with help at every stage of the process

REALIZING THE POTENTIAL OF YOUR RESEARCH

Whether you are looking to publish clinical trial results, describe the design of a new study or provide an in-depth review, you will be fully supported by our team before, during and after publication.

Our unique editorial model, with an in-house, London-based editorial team, means there is a specialist point of contact available at all times. This makes it easy for you to reach an expert in your field, understand the potential of your research and work towards achieving your objectives.

We will assist you with journal selection for a broad range of article types, including:

ORIGINAL RESEARCH
- Pre- and post-registration studies
- Comparative effectiveness research
- Observational studies
- Clinical trial methodologies
- Cost–effectiveness/HEOR studies
- Negative data

SUPPLEMENTARY CONTENT
- Symposia proceedings
- Abstract compilations
- Workshop summaries
- Roundtable discussions

REVIEWS
- Narrative and systematic
- Unmet medical needs
- Multidisciplinary approaches to care
- Evidence-based medicine
- Consensus and treatment guidelines
- Management perspectives
- Therapeutic overviews
- Drug, device and vaccine profiles
- Commentaries on key clinical studies
MEETING PUBLICATION DEADLINES

ACCELERATED PUBLICATION
Your paper will be published in 14 – 16 weeks as standard. If you require a faster option, you can achieve publication in as little as 6 weeks through our accelerated publication service.

A fee of £180/$300/€225 per published page applies for the accelerated publication service. Please note that publication is strictly upon approval by independent peer review.
Enhance your research with award-winning design and high-quality images

ILLUSTRATING YOUR FINDINGS

Upon publication, your research is formatted into an award-winning structure that enhances comprehension and learning.

Our highly specialized in-house graphic and design team can provide a bespoke medical illustration and figure redrawing service. Simply provide us with a basic sketch, and we will provide you with a high-quality image for use in your publication.

The fee for this service varies according to the services required. Please contact us for a quote.
Encourage readers to access and engage with your research

EXTENDING REACH

OPEN & SPONSORED FREE ACCESS
Open Access articles have significantly higher readership and usage than articles behind the subscription barrier. The Gold Open Access option (CC BY-NC-ND) is available to most authors for a flat rate of £1700/$2920/€2135 plus VAT, where applicable.

Open Access is only available to authors. Sponsors or third parties wishing to make an article free to download from our website can provide access by paying the appropriate free access fee. More information on the free access option is available upon request.

ARTICLE & CHAPTER REPRINTS
Our dedicated in-house account managers are available throughout the publication process to discuss the dissemination of your research.

Reprints and ePrints are available from as little as 100 copies and are fully customizable to include bespoke covers, logos and legal disclaimers. Reprints can be delivered to multiple locations worldwide and, using specialist local linguists, can be translated into any language.

BESPOKE SOLUTIONS
Effective communication only starts with publication. To help you meet your goals, your research can be enriched with:

- Webinars hosted by a member of our editorial team
- Video/audio interviews with your lead author
- Video/audio of your conference presentations
- Additional content, hosted on our platform
- Microsites
- Sponsored eBooks
- Direct promotion

Additional opportunities are available via our three eCommunities – Oncology Central, Bioanalysis Zone and RegMedNet (Regenerative Medicine Network). Contact us to learn more.
Future Science Group publishes a constantly expanding group of journals in cutting-edge areas of postgenomic scientific and medical information. Although their topics are diverse, all Future Science Group publications share the following features:

**TIMELY REVIEWS, ORIGINAL RESEARCH & COMMENTARIES**
Our titles blend commissioned and unsolicited content to ensure that readers are kept comprehensively updated on the latest advances and techniques in bioscience and clinical practice, whatever your discipline.

**EASY-TO-READ, STRUCTURED FORMAT**
Quality design enhances comprehension. To speed up learning and save researchers time, articles and chapters are augmented by a specially designed reader-friendly layout.

**ACCELERATED, HIGH-FREQUENCY PUBLICATION**
To keep pace with scientific endeavor, peer-reviewed content is available in as little as 6 weeks from submission. Most articles are published ahead of print, ensuring access to the latest findings.

**GLOBAL VISIBILITY & ACCESSIBILITY**
To ensure 24/7 access, all titles are hosted on Atypon platforms – a market leader in content management. Most articles can be made Open Access on this platform. In addition, many of our journals are indexed on MEDLINE, Thomson Science Citation Index, EMBASE and Chemical Abstracts.
Addressing information needs in clinical and translational medicine and the biosciences

CLINICAL & TRANSLATIONAL MEDICINE

ONCOLOGY
NEWLY LAUNCHED

Hepatic Oncology
Original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations.

International Journal of Endocrine Oncology
Focuses specifically on cancers of the endocrine system itself, with articles targeted to the time-constrained clinician.

Melanoma Management
Clinical aspects of treating a patient with melanoma aimed at the practicing clinician, as well as scientists conducting translational and clinical research.

Future Oncology
MEDLINE-indexed
Impact Factor: 2.611
24 issues per year
22,555 abstract views per month
Rejection rate: 37%
Provides updates on oncology research, ranging from the bench to the bedside

CNS Oncology
MEDLINE-indexed
6 issues per year
715 abstract views per month
Rejection rate: 30%
Clinical and translational research in, and management of, tumors of the central nervous system

Breast Cancer Management
6 issues per year

Colorectal Cancer
6 issues per year

International Journal of Hematologic Oncology
6 issues per year

Lung Cancer Management
6 issues per year

Links to
Oncology Central
www.oncology-central.com
Oncology Central offers easy access to breaking news and peer-reviewed articles in a clinician-curated environment
Shaped to meet the needs of time-constrained practitioners and policy-makers

**CARDIOLOGY**

*Future Cardiology*
- MEDLINE-indexed
- 6 issues per year
- 6650 abstract views per month
- Rejection rate: 44%
- Covers advances in basic, translational and clinical cardiology research

*Clinical Lipidology*
- Impact Factor: 0.855
- 6 issues per year
- 3200 abstract views per month
- Rejection rate: 33%
- Clinical findings and analysis of future trends of the interplay of lipids in health and disease

*Interventional Cardiology*
- 6 issues per year

*Diabetes Management*
- 6 issues per year

**NEUROLOGY**

*Neurodegenerative Disease Management*
- MEDLINE-indexed
- 6 issues per year
- 1395 abstract views per month
- Managing neurodegenerative disease in practice

*Pain Management*
- MEDLINE-indexed
- 6 issues per year
- 2200 abstract views per month
- Rejection rate: 30%
- Latest research findings and reviews in pain medicine

**INFECTION DISEASE**

*Future Microbiology*
- MEDLINE-indexed
- Impact Factor: 3.819
- 12 issues per year
- 17,450 abstract views per month
- Rejection rate: 51%
- Covers microbiological areas including all pathogen types and microbe–host interactions

*Future Virology*
- Impact Factor: 1.0
- 12 issues per year
Highly focused journals covering the fastest growing areas of bioscience

**IMMUNOLOGY**

*Immunotherapy*
- MEDLINE-indexed
- Impact Factor: 2.44
- 12 issues per year
- 9580 abstract views per month
- Rejection rate: 33%
  Therapeutics that harness the immune system to combat disease

*International Journal of Clinical Rheumatology*
- CME articles
- 6 issues per year

**MULTI-DISCIPLINARY**

*Journal of Comparative Effectiveness Research*
- MEDLINE-indexed
- Impact Factor: 1.119
- 6 issues per year
- 2250 abstract views per month
- Rejection rate: 6%
  The only MEDLINE-indexed journal focused specifically on comparative effectiveness research

*Women’s Health*
- MEDLINE-indexed
- CME articles
- 6 issues per year
- 6895 abstract views per month
- Rejection rate: 52%
  Editorials and reviews, drug profiles and clinical trial reports specific to women’s health

*Therapeutic Delivery*
- MEDLINE-indexed
- 12 issues per year
- 6870 abstract views per month
- Rejection rate: 50%
  Comprehensive coverage of all aspects of the evolving drug delivery field

*Biomarkers in Medicine*
- MEDLINE-indexed
- Impact Factor: 2.858
- 12 issues per year

*Clinical Investigation*
- 12 issues per year
Enriched with online communities that facilitate collaboration and innovation

BIOSCIENCE & BIOTECHNOLOGY

**Regenerative Medicine**
MEDLINE-indexed
Impact Factor: 3.5
8 issues per year
11,015 abstract views per month
Rejection rate: 35%
Up-to-date research for the translation of stem cell therapies from the laboratory to patients

Links to RegMedNet
www.regmednet.com
A unique and unparalleled platform for the regenerative medicine community to share insights, discuss the latest research and help move the field forward

**Nanomedicine**
MEDLINE-indexed
Impact Factor: 5.824
24 issues per year
26,364 abstract views per month
Rejection rate: 65%
Advances in medical nanoscale-structured material and devices

**Pharmacogenomics**
MEDLINE-indexed
Impact Factor: 3.425
18 issues per year

**Bioanalysis**
MEDLINE-indexed
Impact Factor: 3.027
24 issues per year

With over 7000 registered users, Bioanalysis Zone is the market-leading online resource for the global bioanalytical community

**Personalized Medicine**
Impact Factor: 1.132
6 issues per year
FREQUENTLY ASKED QUESTIONS

How do I submit? And where can I find the guidelines?
In the first instance, contact a member of our Publishing Solutions team who will talk you through the process and provide you with all relevant information.

Do you charge a submission fee?
No. A fee only applies for accelerated publication and Open Access.

Do you consider industry-sponsored content?
Yes, as long as the sources of funding assistance are fully disclosed from the outset.

How many people review my paper?
A minimum of three – one in-house specialist editor and two external independent experts.

If my paper is rejected, can I revise and resubmit?
Yes. You can resubmit to the same or another journal.

Can you tell me the circulation of a specific journal?
As we offer a range of access options, we feel that circulation is not the most accurate measure of readership. We would be happy to provide you with usage statistics for a journal, or even for a specific article.

What is the geographic distribution of your journals?
All of our journals have an international readership. More details are on page 5.
From pre-publication queries to post-publication support, we are on hand to help

What do you mean by links to eCommunities?
To enhance the usefulness of selected journals, we offer news articles, features and directories, in addition to relevant content on a companion website.

These eCommunities are Bioanalysis Zone, Oncology Central and RegMedNet (Regenerative Medicine Network). More eCommunities are planned to launch soon.

What else do you do to encourage readership?
All of our journals are integrated with Twitter, and several of our journals have sizable LinkedIn groups. On top of this, users can sign up for alerts and email digests. We will be expanding integration with social media in the months ahead.

I have another question.
We’d be happy to help. Contact details are overleaf.
Contact us

Joanne Walker
Senior Manager, Publishing Solutions
📞 +44 (0)20 8371 6090
✉️ j.walker@future-science-group.com
🐦 @JoWFSG

To request a quote for reprints, contact:
📞 +44 (0)20 8371 6090
✉️ reprints@future-science-group.com

Future Science Group
Unitec House
2 Albert Place
London, N3 1QB
United Kingdom
📞 +44 (0)20 8371 6090
✉️ info@future-science-group.com
🌐 www.future-science-group.com
🐦 @futuresciencegp